Fundraising FoxIDience
2 known investors
Find your way into IDience
Sign up to see every warm intro you have to IDience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the IDience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Idience is a biopharmaceutical company focused on developing and commercializing new medicines. Established in 2019 as a wholly owned subsidiary of Korean pharmaceutical group Ildong Holdings.
Also known as Idience Co., Ltd. · 아이디언스
Founders & leadership
Investors · 2
Company profile
researched Aug 2026Idience Co., Ltd. is a clinical-stage biopharmaceutical company based in Seoul, South Korea, focused on the development and commercialization of next-generation oncology medicines. It was established in May 2019 as a wholly owned subsidiary of Ildong Holdings, a Korean pharmaceutical group. The company's stated aim is to advance and accelerate lead candidates from preclinical research into clinical trials for cancer patients.
Its lead program is venadaparib (IDX-1197), a selective PARP inhibitor that prevents repair of DNA single-strand breaks and promotes their conversion into double-strand breaks, leading to synthetic lethality in cancer cells. Venadaparib is in clinical development across multiple solid tumors, both as monotherapy (including maintenance settings) and in combination with other anti-cancer agents. The company launched a Phase 1/2 basket trial (NCT04174716) of IDX-1197 for patients with HRR-mutated solid tumors. Idience also publishes preclinical work comparing venadaparib with other PARP inhibitors.
Founding story
Idience was created in May 2019 by Ildong Holdings, a major Korean pharmaceutical group, as a wholly owned new-drug development subsidiary tasked with advancing oncology candidates into clinical trials.
Traction
Idience opened a Phase 1/2 basket trial (NCT04174716) of IDX-1197 across multiple indications in HRR-mutated solid tumors. Company announcements reference a U.S. FDA Fast Track designation for venadaparib and a joint development agreement with Aptis (앱티스) for a next-generation dual-payload antibody-drug conjugate.
Latest developments
The company's website highlights a U.S. FDA Fast Track designation for its targeted anticancer agent venadaparib and a co-development agreement with Aptis for a next-generation dual-payload ADC. Private-market records list a strategic financing dated May 20, 2024.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Idience is a private, Seoul-based clinical-stage oncology developer operating in the PARP inhibitor and precision-medicine segment. Private-market data sources identify Duke Street Bio, Onconic Therapeutics and Synnovation Therapeutics as comparable companies.
Technology
The company's core asset is venadaparib (IDX-1197, also referenced as ID11916), a potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP). By blocking repair of DNA single-strand breaks, the compound promotes conversion of those breaks into double-strand breaks, producing synthetic lethality in tumor cells with homologous recombination repair (HRR) deficiencies. Development covers monotherapy, maintenance use and combinations with other anti-cancer agents.
Go-to-market
Patients with HRR-mutated and other solid tumors, addressed through oncologists and healthcare institutions; profiles describe target markets including the United States and Europe.
Geography
Headquartered in Seoul, South Korea, with clinical development and stated commercial ambitions extending to the United States and Europe.
History
Idience Co., Ltd. was established in May 2019 as a 100% subsidiary of Ildong Holdings. It progressed its lead PARP inhibitor IDX-1197 (venadaparib) from preclinical research into clinical development, opening a Phase 1/2 basket trial (NCT04174716) in HRR-mutated solid tumors. Third-party private-market profiles record subsequent financing activity in November 2020, July 2022 and May 2024.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsIdience and Aptis signed a joint development agreement for a next-generation dual-payload antibody-drug conjugate.
The company announced that its targeted anticancer agent venadaparib received U.S. FDA Fast Track designation.
Idience launched a Phase 1/2 basket trial of its lead PARP inhibitor IDX-1197 for patients with HRR-mutated solid tumors across multiple indications.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Idienceidience.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does IDience do?
- Korean clinical-stage biopharmaceutical company developing venadaparib (IDX-1197), a PARP inhibitor for solid tumors.
- Who are IDience's investors?
- IDience's investors include DAYLI Partners, Kiwoom Investment.